Intra-Cellular Therapies (ITCI) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Key achievements and financial performance

• Achieved $462 million in revenue last year, an 86% increase from the prior year, and projected $650–$680 million for this year.

• Caplyta's approval for schizophrenia in 2019 and bipolar depression in 2021 drove significant growth.

• First half of this year saw a 50% revenue increase over the same period last year.

• Less than 20% of current prescriptions are for schizophrenia, with bipolar depression now the dominant indication.

• Expanded sales force from 370 to 530 reps, increasing target coverage from 43,000 to 70,000 providers.

Product profile and market differentiation

• Caplyta demonstrates robust efficacy in schizophrenia, bipolar depression, and adjunctive MDD, with effect sizes of 0.6 in MDD.

• Side effect profile is favorable, with metabolic parameters, prolactin, weight gain, and EPS similar to placebo across indications.

• High patient retention and refill rates observed in both schizophrenia and bipolar depression populations.

• Coverage exceeds 99% in public markets and 90% in commercial markets, comparable to established branded antipsychotics.

• Safety and efficacy profile remains consistent across all studied populations.

Market opportunity and strategic expansion

• Bipolar disorder and MDD represent much larger addressable markets than schizophrenia, with 11 million and 21 million patients, respectively.

• Expansion into primary care is underway, with primary care now accounting for 25% of bipolar scripts.

• The company is preparing for a potential label expansion for adjunctive MDD, with filing planned for this half of the year and a standard 10-month review expected.

• Sales force expansion positions the company to capitalize on broader MDD and bipolar opportunities.

• Focus remains on mood disorders as the primary growth engine, with schizophrenia now a smaller revenue contributor.